Advertisement

Advertisement
Mary Pasquinelli, DNP, APRN, FNP-BC, on Addressing Lung Cancer Care Equity in Vulnerable Communities

Mary Pasquinelli, DNP, APRN, FNP-BC, on Addressing Lung Cancer Care Equity in Vulnerable Communities

Adjuvant Irinotecan/Cisplatin vs Etoposide/Cisplatin for Resected High-Grade Neuroendocrine Carcinoma of the Lung

In a Japanese phase III trial reported in the Journal of Clinical Oncology, Kenmotsu et al found that adjuvant irinotecan/cisplatin did not improve relapse-free survival vs etoposide/cisplatin in patients with completely resected, pathologic stage I–IIIA, high-grade neuroendocrine carcinoma of the lung.

Study Finds State-Level Lung Cancer Screening Rates Not Aligned With Lung Cancer Burden in the United States

Study Finds State-Level Lung Cancer Screening Rates Not Aligned With Lung Cancer Burden in the United States

A new study published by Stacey A. Fedewa, PhD, and colleagues in JNCI: Journal of the National Cancer Institute found that state-level lung cancer screening rates were not aligned with the national lung cancer burden. The report provides the first population-based state-level screening data for all 50 states and notes lung cancer screening rates varied geographically by state.

Lung Cancer: Precision Therapies at the Forefront

Lung Cancer: Precision Therapies at the Forefront

"In the year 2020 alone, the U.S. Food and Drug Administration approved nine new indications for lung cancer; four represented novel agents approved for the first time (selpercatinib, pralsetinib, lurbinectedin, capmatinib), and three were new indications for immunotherapy agents. In all, the treatment of NSCLC has been transformed in the past few years," writes Suresh S. Ramalingam, MD, FACP, FASCO.

Biomarker-Driven Master Protocol to Test Therapies for Previously Treated Patients With Squamous NSCLC

In an article published in The Lancet Oncology, Redman et al described the conduct of and findings from the Lung Cancer Master Protocol, a completed biomarker-driven master protocol designed to address the need for improved therapies for previously treated patients with squamous non­–small cell lung cancer (NSCLC).

Multisystem Immune-Related Adverse Events and Disease Outcomes Among Patients With NSCLC Treated With Immunotherapy

In a retrospective cohort study reported in JAMA Oncology, Shankar et al found improved progression-free and overall survival among patients who experienced multisystem immune-related adverse events after anti–PD-1 or anti–PD-L1 immune checkpoint inhibitor therapy for stage III/IV non–small cell lung cancer (NSCLC).

Advertisement


Advertisement